Acrobiosystems Co

Acrobiosystems Co Assets per Share

The Total Assets per Share of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 18.00 CNY. In the previous year, Total Assets per Share was 17.43 CNY — a change of 3.26% (higher).

Assets per Share

18.00CNY

YoY

3.26%

Last updated:

Total Assets per Share of Acrobiosystems Co is 2025 18.00 CNY. Total Assets per Share of Acrobiosystems Co was 2024 17.43 CNY. It decreases by 3.26% higher compared to the previous year.

The Acrobiosystems Co Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
0.50 CNY
Jan 1, 2019
0.68 CNY
Jan 1, 2020
1.44 CNY
Jan 1, 2021
15.22 CNY
Jan 1, 2022
16.37 CNY
Jan 1, 2023
16.83 CNY
Jan 1, 2024
17.43 CNY
Jan 1, 2025
18.00 CNY
The Acrobiosystems Co Assets per Share history
YEARAssets per ShareYoY
18.00CNY+3.26%
17.43CNY+3.59%
16.83CNY+2.83%
16.37CNY+7.51%
15.22CNY+954.44%
1.44CNY+112.71%
0.68CNY+35.93%
0.50CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Total Assets per Share of Acrobiosystems Co is 18.00 CNY in 2025.

Total Assets per Share of Acrobiosystems Co changed from 17.43 CNY to 18.00 CNY, representing a 3.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co